A-01

NMO-IgG blocker A-01 is a idiotype-specific blocker of neuromyelitis opticaimmunoglobulin g (nmo-igg) binding to aquaporin-4 (aqp4)

A 83-01 (ALK5 Inhibitor IV) is an inhibitor of the TGF-β type I receptors ALK5, ALK4, and ALK7 (IC50=12/45/7.5 nM). A 83-01 promotes the reprogramming of mouse fibroblasts into iPSCs. A 83-01 can be used in organoid cultures.

GA-017 is a potent, selective inhibitor of LATS1 and LATS2 (large tumor suppressor kinase 1/2), exhibiting IC50 values of 4.10 and 3.92 nM, respectively. This compound simultaneously acts as an activator of cell proliferation by promoting YAP/TAZ activation and their nuclear translocation. Additionally, GA-017 enhances cell growth in 3D culture conditions and augments the ex vivo formation of mouse intestinal organoids [1].

A 83-01 sodium salt is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC 50 s of 12 nM, 45 nM and 7.5 nM against the ALK5, ALK4 and ALK7 induced transcription, respectively [1].

A 77-01 is a potent inhibitor of the TGF-(beta) type I receptor superfamily activin-like kinase ALK5, with an IC50 of 25 nM.

OXA-01 is a potent mTORC1 (IC50: 29 nM) and mTORC2 (IC50: 7 nM) inhibitor, demonstrating broad anti-tumor activity [1].

3HOI-BA-01 is a mammalian targeting effective rapamycin activation inhibitor.

TA-01 is a potent inhibitor of CK1 and p38 MAPK, with IC50 values of 6.4 nM for CK1ε, 6.8 nM for CK1δ, and 6.7 nM for p38 MAPK.

WU-FA-01, a hydrogenated derivative of WU-FA-00, is an antibacterial agent with robust activity against Gram-positive strains and possesses anti-inflammatory properties [1].

Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a mouse IgG1 kappa antibody produced in vivo, specifically targeting the SARS-CoV-2 S protein. The recommended isotype control for this antibody is Mouse IgG1 kappa, Isotype Control.

NRA-0160 is a selective antagonist of dopamine D4 receptor(Ki of 0.48 nM)

DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba F3-EGFR Del19 T790M C797S (IC50= 6.9 nM), Ba F3-EGFR WT (IC50= 0.83 μM), Ba F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.

TYA-018 is an orally available and selective HDAC6 inhibitor with cardioprotective properties for the study of dilated heart disease and heart failure.TYA-018 prevents sarcomere damage and decreases Nppb expression.

Smurf1-IN-A01 (A01) is a ubiquitin ligase Smad ubiquitination regulatory factor-1 inhibitor (Kd: 3.664 nM) that enhances BMP-2 responsiveness by preventing Smurf1-mediated Smad1/5 degradation.

CHIR-99021 (CT99021) is an activator of the Wnt/β-catenin signaling pathway and a GSK-3α/β inhibitor (IC50=10/6.7 nM) with selective and oral activity.CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.

Peliglitazar racemate(BMS 426707-01 racemate) is the racemate of Peliglitazar.Peliglitazar racemate may be used as a potential antidiabetic and anti-obesity agent.

LY3295668 (AK-01) is a selective inhibitor of Aurora A, with Ki values of 0.8 nM for Aurora A and 1038 nM for Aurora B.

HTH-01-015 is a selective NUAK1 inhibitor with an IC50 of 100 nM.

HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM) that also inhibits PIM1 2 3, RIPK2, DYRK3, smMLCK, and CLK2. It can be used to study breast cancer.

Pyrazinecarboxamide, 3,4-dihydro-4-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-3-oxo- is a useful organic compound for research related to life sciences. The catalog number is TNU0422L and the CAS number is 356783-01-2.This compound is unstable in powder form and other related salt forms are recommended.

Compound FL0001, with CAS No. 479553-01-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0001 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound FL0275, with CAS No. 832-01-9, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound FL0275 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr12161, with CAS No. 16502-01-5, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr12161 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr12484, with CAS No. 3764-01-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr12484 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.